使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and welcome to today's DexCom fourth quarter and full year 2007 earnings results conference call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following today's presentation, we will conduct a question-and-answer session. Instructions will be provided at that time. At this time for opening remarks, I would like to turn the call over to Mr. Terry Gregg, President and CEO. Please go ahead, sir.
各位好,歡迎參加今天 DexCom 2007 年第四季及全年財報結果電話會議。今天的會議將被錄音。目前所有與會者皆處於僅收聽模式。在今天的簡報結束後,我們將進行問答環節,屆時會提供相關指示。現在進入開場致詞,我想把電話交給總裁暨執行長 Terry Gregg 先生。先生,請開始。
- President, CEO
- President, CEO
Thank you, and good afternoon, everyone. I'm excited to give you an update for the full year 2007, and to go through our agenda, but we'll first start off with having Steve Pacelli, our Senior Vice President of Corporate Affairs go through a Safe Harbor statement. Steve?
謝謝,各位下午好。我很高興向各位更新 2007 全年的情況並帶各位走過今天的議程。不過我們會先請公司事務資深副總裁 Steve Pacelli 宣讀「安全港」聲明。Steve?
- SVP, Corporate Affairs
- SVP, Corporate Affairs
Thank you, Terry. Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans and performance and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under Risk Factors and elsewhere in our annual report on Form 10-K, our quarterly reports on 10-Q and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these statements for any reason. Terry?
謝謝你,Terry。我們在今天電話會議中所做的部分陳述可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅以本日為準。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何此類前瞻性陳述所明示或暗示者出現重大差異的因素清單,已在我們的 Form 10-K 年報之「風險因素」及其他章節、Form 10-Q 季報,以及我們向 SEC 提交的其他報告中詳述。我們不承擔因任何理由而公開更新或修訂這些陳述的義務。Terry?
- President, CEO
- President, CEO
Thanks, Steve. I will give you a brief idea of the agenda today. We are going to go through the financial review. Jess Roper, our Interim CFO, is going to present the data. Next, commercialization update, followed by our partnership update, a development and regulatory update, remarks on our in-hospital, continuous glucose monitoring. We'll give you a brief preview and review of what we are doing on the reimbursement side and summarize and conclude the call. Jess?
謝謝,Steve。我先簡要說明今天的議程。我們將進行財務回顧,由我們的代理財務長 Jess Roper 來呈現數據。接著是商業化進度更新,然後是合作夥伴關係更新、研發與法規進度更新,以及我們在院內連續血糖監測方面的說明。我們也會簡要預告並回顧我們在給付(reimbursement)方面所做的工作,最後總結並結束本次電話會議。Jess?
- Interim CFO
- Interim CFO
Great, thank you, Terry. DexCom reported revenues of $4.6 million for the year ended 2007, compared to $2.2 million in 2006. Sequentially revenues increased 25% from the third quarter of 2007, and totaled $1.5 million for Q4. We added approximately 840 new customers during Q4. As of December 2007, we have upgraded over 1200 first generation three-day customers to our second generation Seven System. Sensor revenues were up 39% sequentially from Q3. A small portion of our Q4 sales -- excuse me, a small portion of our Q4 Sensor sales included first generation three-day sensors. We anticipate the sales of these first generation sensors to end near the latter part of the first quarter of 2008.
很好,謝謝你,Terry。DexCom 2007 年度營收為 460 萬美元,相較於 2006 年的 220 萬美元。按季而言,營收較 2007 年第三季成長 25%,第四季合計為 150 萬美元。我們在第四季新增約 840 位新客戶。截至 2007 年 12 月,我們已將超過 1,200 位第一代三日系統客戶升級至第二代 Seven 系統。感測器營收較第三季按季成長 39%。我們第四季的感測器銷售中有一小部分—抱歉,是第四季感測器銷售的一小部分—仍包含第一代三日感測器。我們預期這些第一代感測器的銷售將在 2008 年第一季後段附近結束。
Cost of sales for the year ended 2007, totaled $12.7 million, compared to $11 million in 2006. The increase was primarily due to greater product sales and included additional fixed overhead spending. Our gross margin loss for 2007 was $8.1 million, compared to a loss of $8.8 million in 2006. Research and development expense decreased $3.3 million to $16.1 million for 2007, compared to $19.4 million in 2006. Changes in R&D expense included lower tooling, facilities, and share-based compensation costs. SG&A expense totaled approximately $22 million in 2007, compared to $21 million in 2006. The increase was primarily attributed to $3.5 million additional selling related costs as we incurred such costs for a full 12 months in 2007, compared to lower levels incurred throughout 2006 when we were building our sales force. The $3.5 million increase in selling-related costs was partially offset by $2.4 million in lower marketing costs in 2007.
2007 年度銷貨成本合計 1,270 萬美元,相較於 2006 年的 1,100 萬美元。增加主要是因為產品銷售增加,並包含額外的固定製造費用支出。2007 年毛利損失為 810 萬美元,相較於 2006 年損失 880 萬美元。2007 年研發費用較 2006 年的 1,940 萬美元減少 330 萬美元至 1,610 萬美元。研發費用的變動包含模具、設施以及以股份為基礎之薪酬成本降低。2007 年銷售、一般及行政(SG&A)費用合計約 2,200 萬美元,相較於 2006 年的 2,100 萬美元。增加主要歸因於額外 350 萬美元的銷售相關成本,因為 2007 年我們承擔該等成本為完整 12 個月,而 2006 年在建立銷售團隊期間所發生的成本水準較低。銷售相關成本增加 350 萬美元,部分被 2007 年行銷成本降低 240 萬美元所抵銷。
Net interest income totaled approximately $800,000 for 2007, compared to $2.7 million in 2006. The decrease in net interest income was due to additional interest expense related to the $60 million in convertible senior notes that we issued in March of 2007. Our net loss was down slightly from the prior year and totaled $45.9 million in 2007, compared to $46.6 million in 2006. There was approximately $9 million of noncash expense relating to share-based compensation, depreciation and amortization in 2007, which was up from $8.6 million in 2006. We ended the year with $64 million in cash and marketable securities and working capital of $59 million. During the year, we invested $3.5 million in capital equipment and facilities to support our business. In January of 2008, we admitted our equipment line that allows us to borrow an additional $3 million for the purchase of equipment and other related items.
2007 年淨利息收入合計約 80 萬美元,相較於 2006 年的 270 萬美元。淨利息收入下降係因 2007 年 3 月我們發行 6,000 萬美元可轉換優先票據所產生的額外利息費用。我們的淨損較前一年略為下降,2007 年合計 4,590 萬美元,相較於 2006 年的 4,660 萬美元。2007 年約有 900 萬美元的非現金費用,與以股份為基礎之薪酬、折舊與攤銷相關,高於 2006 年的 860 萬美元。年底我們持有 6,400 萬美元的現金及有價證券,營運資金為 5,900 萬美元。年度期間,我們投資 350 萬美元於資本設備與設施以支援業務。2008 年 1 月,我們修訂了設備額度,使我們得以為購置設備及其他相關項目額外借款 300 萬美元。
I would like to now turn it back to our CEO and President, Terry Gregg.
我現在想把電話交回給我們的總裁暨執行長 Terry Gregg。
- President, CEO
- President, CEO
Thanks, Jess. As we near the end of the first quarter of 2008, we continued to be extremely pleased with the performance of the Seven, our second generation continuous glucose monitoring system. We believe the Seven is proving to be the industry-leading CGM product with noticeable performance benefits and greater ease of use for our patients versus our competition. We believe the Seven continues to create the positive experiences for patients and healthcare professionals that we need to build this emerging category.
謝謝你,Jess。隨著我們接近 2008 年第一季末,我們仍對 Seven(我們第二代連續血糖監測系統)的表現感到非常滿意。我們相信 Seven 正在證明其為業界領先的 CGM 產品,與競爭對手相比,為病患帶來明顯的效能優勢與更高的易用性。我們相信 Seven 持續為病患與醫療專業人員創造我們建立這個新興類別所需的正向體驗。
Highlighting some key performance metrics for the fourth quarter, and full year 2007, as Jess mentioned, revenue grew 25%, sequentially from Q3 to Q4, and was up 113% from 2006, and adding approximately 840 new customers in the fourth quarter, we continued to see an increase in the number of new patients added in our key accounts. In addition, we have successfully upgraded over 1,200 of our existing customers from the STS three day to the seven day system, as of the end of 2007. We expect to continue to upgrade STS three-day customers during Q1 '08 as we look to discontinue production of the STS three-day entirely by the end of Q1 this year. Most encouraging for the long-term viability of the business was a 39% increase in Sensor revenues, quarter to quarter, and a 98% increase compared to the fourth quarter of 2006.
就第四季與 2007 全年的一些關鍵績效指標而言,如 Jess 所提到,營收自第三季到第四季按季成長 25%,較 2006 年成長 113%;第四季新增約 840 位新客戶,我們也持續看到在主要客戶(key accounts)中新增病患人數的增加。此外,截至 2007 年底,我們已成功將超過 1,200 位既有客戶從 STS 三日系統升級至七日系統。我們預期在 2008 年第一季將持續升級 STS 三日客戶,並計畫在今年第一季末前全面停止 STS 三日系統的生產。對於業務長期可行性最令人鼓舞的是,感測器營收季對季成長 39%,且相較 2006 年第四季成長 98%。
As we look to the first half of 2008, we will continue to focus our selling efforts on approximately the largest 100 diabetes centers in the U.S. At this point, we continue to believe our sales force is appropriately sized at approximately 45 field-based individuals, however, as we look to expand our reach into additional diabetes centers in the second half of 2008, we may expand the size of the sales force slightly. Additionally, we may expand the size of the sales force based on the positive momentum we are beginning to see on the reimbursement front.
展望 2008 年上半年,我們將持續把銷售重點放在美國約前 100 大糖尿病中心。目前我們仍認為,我們約 45 位以外勤為主的銷售人員規模是適當的;然而,隨著我們在 2008 年下半年擴大觸及更多糖尿病中心,我們可能會小幅擴編銷售團隊。此外,基於我們在給付(reimbursement)方面開始看到的正向動能,我們也可能擴大銷售團隊規模。
Finally, we are excited to report that recent clinical trial data related to our continuous glucose monitoring products will be presented at the scientific sessions meeting of the annual American Diabetes Association in June, 2000. Two of the studies include a study conducted in December of 2007, in which investigators concluded that patients could wear the Seven safely and effectively for up to 10 days, and a second study also conducted in December, where investigators evaluated alternate site sensor placement, including on the upper arm and hip, and concluded that our next generation sensor performed safely and effectively in these alternate sites. We have consistently maintained that an open architecture, whereby our Sensor technology is adaptable to multiple insulin delivery models represents the best interest of diabetes patients and DexCom.
最後,我們很高興報告,與我們連續血糖監測產品相關的近期臨床試驗數據,將於 2000 年 6 月在美國糖尿病學會(American Diabetes Association)年度科學會議上發表。其中兩項研究包括:一項於 2007 年 12 月進行的研究,研究人員結論認為病患可安全且有效地配戴 Seven 長達 10 天;以及另一項同樣於 12 月進行的研究,研究人員評估了替代部位的感測器放置方式,包括上臂與髖部,並結論認為我們的下一代感測器在這些替代部位同樣能安全且有效地運作。我們一貫主張採用開放式架構,使我們的感測器技術可適配多種胰島素輸注模式,最符合糖尿病病患與 DexCom 的最佳利益。
To that end, in January of this year, we announced two separate development agreements, one with Animas Corporation and one with Insulet Corporation, to development integrated insulin pump CGM systems. In each case, DexCom CGM data will be displayed on the partner's pump, in addition to insulin dosing information, the patients will have access to glucose trend information, as well as high and low alarms, all in a single display unit. Our plan is to integrate DexCom's proprietary software and hardware design into the partner's durable equipment to enable wireless receipt of continuous glucose monitoring data by the pump, thereby eliminating the need for a separate DexCom receiver. Our partners will have primary responsibility for sales and marketing efforts related to CGM-enabled hardware. In each case, DexCom will maintain all revenue from sales of disposable CGM sensors for use with the integrated systems. We envision a Powered by DexCom branding and co-branding of these integrated systems and we believe this model will result in additional feet on the street without additional cost to DexCom.
為此,我們在今年一月宣布了兩項獨立的開發協議,一項與 Animas Corporation,另一項與 Insulet Corporation,旨在開發整合式胰島素幫浦與 CGM 系統。在每一種情況下,DexCom 的 CGM 數據將顯示在合作夥伴的幫浦上;除胰島素劑量資訊外,病患也將可在單一顯示裝置上取得葡萄糖趨勢資訊,以及高、低值警報。我們的計畫是將 DexCom 專有的軟體與硬體設計整合至合作夥伴的耐用設備中,使幫浦能以無線方式接收連續葡萄糖監測資料,從而免除另行使用 DexCom 接收器的需求。我們的合作夥伴將對與具 CGM 功能之硬體相關的銷售與行銷工作負主要責任。在每一種情況下,DexCom 將保留整合系統所使用之一次性 CGM 感測器銷售的全部營收。我們設想採用 Powered by DexCom 品牌與共同品牌策略來推廣這些整合系統,並相信此模式將在不增加 DexCom 額外成本的情況下,帶來更多前線銷售人員。
With regards to patients and patient support, patients using the integrated system are DexCom patients for purposes of continuous glucose monitoring. DexCom will maintain responsibility for ongoing patient support, with respect to CGM, while each partner will be responsible for ongoing patient support with respect to insulin pump therapy. To remind you, these are nonexclusive relationships. DexCom will continue to market and sell stand alone CGM systems. Our partners will continue to market and sell stand alone pumps and all parties are tree to enter into similar relationships with third parties. With regards to timing of product availability, our goal in each case is to move rapidly to capitalize and integrate existing technology platforms to bring first generation products to market and follow quickly with next generation product iterations.
就病患與病患支援而言,使用整合系統的病患在連續葡萄糖監測方面屬於 DexCom 的病患。DexCom 將持續負責與 CGM 相關的後續病患支援,而各合作夥伴則將負責與胰島素幫浦治療相關的後續病患支援。提醒各位,這些皆為非獨家合作關係。DexCom 將持續行銷並銷售獨立式 CGM 系統。我們的合作夥伴也將持續行銷並銷售獨立式幫浦,且各方均可自由與第三方建立類似合作關係。就產品上市時程而言,我們在每一種情況下的目標都是迅速推進,利用並整合既有技術平台,將第一代產品推向市場,並隨後快速推出下一代產品迭代。
In our ongoing discussions with the Food and Drug Administration, we have confirmed that these combined systems will be premarket approved devices, or in our case, supplements to our existing DMA. As a result, DexCom will lead all regulatory testing, trials and filings related to the integrated systems with partner support. To that end, Animas will contribute up to $750,000 to DexCom to offset certain development, clinical and regulatory expenses in connection with the Animas integration. Each party remains independently responsible for maintaining appropriate regulatory approvals for their stand alone products. Our goal is to complete all development, clinical and regulatory efforts with at least one partner and be positioned to launch a first product during the summer of 2009, but as the regulatory process is uncertain, that timing could slip by several months.
在我們與美國食品藥物管理局(FDA)的持續討論中,我們已確認這些組合系統將屬於上市前核准(PMA)器材,或就我們而言,為對既有 DMA 的補充。因此,DexCom 將在合作夥伴支援下,主導與整合系統相關的所有法規測試、試驗與申報。為此,Animas 將提供最高 750,000 美元予 DexCom,以抵銷與 Animas 整合相關的部分開發、臨床與法規費用。各方仍各自獨立負責維持其獨立產品所需的適當法規核准。我們的目標是與至少一家合作夥伴完成所有開發、臨床與法規工作,並在 2009 年夏季推出首款產品;但由於法規流程具有不確定性,該時程可能延後數個月。
Aside from insulin delivery, we continue to explore opportunities for continuous glucose monitoring to be used together with other diabetes drugs and devices to improve the convenience and effectiveness of diabetes management. We are currently participating in, or evaluating the use of CGM in studies with long acting [exenotide] inhaled insulin and insulin patches, among other technologies. Finally, we have recently become involved in a JDRF-sponsored research and development project with ultimate goal of closing the loop.
除胰島素輸注之外,我們也持續探索將連續葡萄糖監測與其他糖尿病藥物與器材結合使用的機會,以提升糖尿病管理的便利性與有效性。我們目前正參與或評估在研究中使用 CGM,涵蓋長效型 [exenotide]、吸入式胰島素與胰島素貼片等技術。最後,我們近期也參與了一項由 JDRF 贊助的研發專案,其最終目標是實現閉環控制。
We have long held that the continual introduction of next generation products with improved performance and patient convenience are key to the development and the growth of the continuous glucose monitoring category. In November of 2007, we received FDA approval to add additional functionality to the Seven to enable patients to calibrate the system using any brand of approved blood glucose meter, and we launched this feature which we branded Open Choice in February of this year. We plan to offer an upgrade to existing patients in the second quarter of 2008. In January this year, we received approval to move manufacturing of our Sensor applicated subassembly to an outside vendor. We believe this will better enable us to scale Sensor manufacturing as demand increases and reduce manufacturing costs over time.
我們長期以來一直認為,持續推出具更佳效能與更高病患便利性的下一代產品,是連續葡萄糖監測類別發展與成長的關鍵。2007 年 11 月,我們獲得 FDA 核准,為 Seven 增加額外功能,使病患可使用任何品牌的核准血糖機來校正系統;我們並於今年 2 月推出此功能,並將其命名為 Open Choice。我們計畫在 2008 年第二季向既有病患提供升級。於今年 1 月,我們獲准將感測器施用器子組件的製造移轉至外部供應商。我們相信,這將使我們能在需求增加時更有效擴大感測器製造規模,並隨時間降低製造成本。
We completed a pivotal trial in December of 2007 for a third generation continuous glucose monitoring system. Results across all trial sites showed performance equivalent to the Seven and we believe the data set is sufficient for filing a DMA supplement. However, we elected to delay filing a PMA supplement as our analysis determined that our Gen 3 Sensor as built for the pivotal trial is 10% more expensive to build, due to increased labor and materials while offering only incremental performance gains over the Seven. Our continued R&D efforts during this quarter have resulted in the development of a modified Gen 3 sensor with improved performance and convenience without added costs. We expect to complete a small additional clinical trial in early Q2, with a PMA supplement filing to follow quickly thereafter.
我們於 2007 年 12 月完成第三代連續葡萄糖監測系統的關鍵性試驗。各試驗中心的結果顯示其效能與 Seven 相當,我們相信該資料集足以提交 DMA 補充申請。然而,我們選擇延後提交 PMA 補充申請,因為我們的分析顯示,用於關鍵性試驗的第三代感測器(Gen 3 Sensor)在製造上因增加人工與材料而成本高出 10%,但相較 Seven 僅帶來有限的效能提升。本季持續的研發工作已促成一款經修改的第三代感測器,在不增加成本的情況下提升效能與便利性。我們預期在第二季初完成一項小型追加臨床試驗,並在其後迅速提交 PMA 補充申請。
We are also preparing to file a PMA supplement with the FDA, which will add additional functionality into our Data Management Two software, including the feature to allow our customers to update their receiver firmware over the Internet. Internationally, we continue to pursue a CE mark for the Seven and to that end we are currently working with a notified body in Europe to review our quality systems and assist us in obtaining a CE mark. We expect to submit our technical file in the second quarter of 2008 and we hope to complete our ISO audit during the their quarter of this year.
我們也正準備向 FDA 提交一項 PMA 補充申請,將額外功能加入我們的 Data Management Two 軟體,其中包括允許客戶透過網際網路更新其接收器韌體的功能。在國際方面,我們持續推進 Seven 的 CE 認證;為此,我們目前正與歐洲的公告機構合作,審查我們的品質系統並協助取得 CE 認證。我們預期在 2008 年第二季提交技術檔案,並希望在今年第三季完成 ISO 稽核。
We attended both the study group on artificial insulin delivery, pancreas, and eyelet transplantation meeting in Australia in January and the first international conference on advanced technologies and treatments for diabetes meeting in Prague last month, where we met key opinion leaders in diabetes from around the globe. We have identified the principal investigators who we will work with to conduct a clinical trial in Europe later this year and the protocol is currently under development. We expect to start this trial sometime after the European Association For the Study of Diabetes Meeting in Rome later this summer. Finally, we are pleased to report that we have completed the buildout and have successfully transitioned a large portion of our operations into our new corporate headquarters and expect to complete the move of our manufacturing operations during the second quarter of this year.
我們於一月在澳洲參加了人工胰島素輸注、人工胰臟與胰島移植研究小組會議,並於上月在布拉格參加了第一屆糖尿病先進技術與治療國際會議,期間與來自全球的糖尿病領域關鍵意見領袖會面。我們已確認將合作於今年稍晚在歐洲進行臨床試驗的主要研究者,目前試驗方案正在制定中。我們預期在今年夏末於羅馬舉行的歐洲糖尿病研究協會(EASD)年會之後的某個時間啟動該試驗。最後,我們很高興報告,我們已完成擴建,並已成功將營運的大部分轉移至新的公司總部,並預期於今年第二季完成製造作業的搬遷。
I would like to move on to the in hospital continuous glucose monitoring project. We continue to make tremendous progress in the development of a system to address the critical care market. As we estimate approximately 45% of U.S. hospitals have or are in the process of implementing tight glycemic control protocols to reduce mortality and morbidity in their postsurgical patients. We recognize the need to increase our efforts in this key area for continuous glucose monitoring. At the recent Society For Critical Care annual meeting with over 4,000 attendees, the consensus was that tight glycemic control is the new standard of care in the ICU. As recent studies have shown, however, the major challenge is the detection of hypoglycemia, requiring numerous additional bedside fingerstick measurements to avoid.
我想接著談院內連續葡萄糖監測專案。我們在開發一套可滿足重症照護市場需求的系統方面持續取得重大進展。據我們估計,美國約有 45% 的醫院已經或正在導入嚴格血糖控制(tight glycemic control)流程,以降低術後病患的死亡率與罹病率。我們認知到在連續葡萄糖監測這一關鍵領域需要加大投入。在近期有超過 4,000 名與會者的重症醫學會(Society For Critical Care)年度會議上,共識認為嚴格血糖控制已成為加護病房(ICU)的新照護標準。然而,近期研究也顯示,主要挑戰在於低血糖的偵測,為避免低血糖往往需要進行大量額外的床邊指尖採血測量。
We believe that our hospital blood glucose monitoring system solves this challenging with programmable measurements as frequently as five minute intervals and preset alarms to detect both hypo and hyperglycemia, similar to our commercially ambulatory system. We are extremely pleased with the results of our latest feasibility trials, in which we have been able to demonstrate prospective accuracy in a porcine model with 100% of data points meeting the ISO standard for therapeutic use. We expect to continue development efforts, culminating in a pivotal trial and a regulatory submission before the end of 2008. This would enable us to commercialize a first product in the second half of 2009. We believe the most efficient means of commercializing our in-hospital system is through an established partner with experience in the critical care market. To that end, we have initiated numerous discussions with a number of potential business partners about opportunities to participate in the design, development, and commercialization of our system.
我們相信,我們的院內血糖監測系統可透過可程式化的測量(最頻繁可達每 5 分鐘一次)以及預設警報來偵測低血糖與高血糖,從而解決此一挑戰,其方式類似於我們商用的攜帶式系統。我們對最新可行性試驗結果感到非常滿意;在豬隻模型中,我們已能證明前瞻性準確度,且 100% 的資料點符合 ISO 治療用途標準。我們預期將持續推進開發工作,並在 2008 年底前完成關鍵性試驗與法規申報。這將使我們能在 2009 年下半年將首款產品商業化。我們認為,將院內系統商業化的最有效方式,是透過在重症照護市場具經驗的既有合作夥伴。為此,我們已就參與我們系統的設計、開發與商業化之機會,與多家潛在商業合作夥伴展開多項討論。
On the reimbursement front, we are pleased to note that we are beginning to see momentum build in both the adoption of coverage policies for CGM by third parties and in their willingness to enter into contracts with DexCom to cover CGM. We are also pleased to note that [hic fix] codes covering the three components of our Seven System became effective on January 1st, 2008. We continue to receive unsolicited reports from patients and physicians of favorable individual coverage decisions and our own reimbursement organization is working to build upon these experiences to push for coverage with private payors. We have also recently implemented a pilot program with a third-party claims negotiation and processing organization and expect to leverage this relationship to help our patients navigate the reimbursement maze.
在報銷方面,我們很高興注意到,我們開始看到動能正在形成:一方面,第三方對 CGM 的給付政策採用正在增加;另一方面,他們也更願意與 DexCom 簽訂合約以涵蓋 CGM。我們也很高興注意到,涵蓋我們 Seven System 三個組件的 [hic fix] 代碼已於 2008 年 1 月 1 日生效。我們持續收到病患與醫師主動回報的個案給付有利決定,而我們自身的報銷團隊也正以這些經驗為基礎,推動私人保險支付方的給付。我們最近也與一家第三方理賠協商與處理機構實施試點計畫,並預期運用這項合作關係,協助我們的病患在報銷迷宮中找到路徑。
Our mission in 2008 is to continue to educate the private payer community on the role of CGM in assisting patients to better manage their glucose excursions, for both hypoglycemia and hyperglycemia. The Juvenile Diabetes Research Foundation sponsored randomized reimbursement trial was fully enrolled at the end of 2007, and we continue to participate in this key critical study. We believe JDRF intends to release an interim six-month data set during the summer of '08. We continue to see reimbursement as one of the key challenges to achieving wide spread adoption of CGM and reiterate that the reimbursement process as we all well know, takes time, patience and perseverance.
我們在 2008 年的使命,是持續教育私人支付方社群,讓其了解 CGM 在協助病患更好管理血糖波動(無論是低血糖或高血糖)方面所扮演的角色。由青少年糖尿病研究基金會(JDRF)贊助的隨機報銷試驗已於 2007 年底完成收案,我們仍持續參與這項關鍵研究。我們相信 JDRF 計畫在 08 年夏季發布一份六個月的期中資料集。我們仍將報銷視為實現 CGM 廣泛採用的主要挑戰之一,並再次強調:如同大家所熟知,報銷流程需要時間、耐心與毅力。
In summary, we believe we are on the cusp of a major transition to the understanding of the significant consequences of excessive glycemic variability. Not only in patients with diabetes, but also in non-diabetes patients, experiencing stress hyperglycemia. The key thought leaders from around the world are cautioning that even a single spike of glucose results in an increase in oxidated stress, and a cascade of proinflammatory agents physiologically. Continuous glucose monitoring is the only tool that can identify glycemic variability and allow patients and healthcare providers to utilize treatment modalities pharmacologically and mechanically to help patients stay between the lines. A1C is a surrogate market but not a very good one. Two patients with identical A1Cs can have far different glycemic profiles but without continuous glucose monitoring, it goes undetected.
總結而言,我們相信我們正處於一個重大轉變的臨界點:人們將理解過度血糖變異所帶來的重大後果。不僅是在糖尿病患者身上,也包括在承受壓力性高血糖的非糖尿病患者身上。來自全球的關鍵意見領袖警示,即便只是一次血糖尖峰,也會導致氧化壓力增加,並在生理上引發一連串促發炎因子。連續血糖監測是唯一能夠辨識血糖變異、並讓病患與醫療照護提供者能以藥物與機械方式運用治療手段,協助病患把血糖維持在目標範圍內的工具。A1C 是一個替代性指標,但並不是很好的指標。兩位 A1C 相同的病患,其血糖曲線可能差異很大,但若沒有連續血糖監測,這些差異就不會被發現。
Our goal is to be the industry leader. We believe our technology is the most accurate over time, and has demonstrated the shortest lag time when compared to capillary blood and is today the only glucose sensor to be approved for up to seven continuous days of use. Finally, and again, we believe as much as ever, that CGM will play a critical role in the future of diabetes management, and will be a growing and profitable business for DexCom. Thank you.
我們的目標是成為產業領導者。我們相信我們的技術在長時間使用下最為精準,且與毛細血管血相比已證明具有最短的延遲時間,並且目前是唯一獲准可連續使用長達七天的葡萄糖感測器。最後,再次強調,我們比以往任何時候都更相信 CGM 將在糖尿病管理的未來扮演關鍵角色,並將成為 DexCom 一項成長且具獲利性的業務。謝謝。
Operator
Operator
Thank you. (OPERATOR INSTRUCTIONS). We will go first to Thom Gunderson with Piper Jaffray.
謝謝。(接線員指示)。我們先請 Piper Jaffray 的 Thom Gunderson 提問。
- Analyst
- Analyst
Hi. Good afternoon, guys.
嗨,各位下午好。
- President, CEO
- President, CEO
Hi, Tom.
嗨,Tom。
- Analyst
- Analyst
I just want to make sure I understood this right, are you -- Terry, did you say that you are moving from a focus on the top 50 centers to the top 100?
我只是想確認我理解正確——Terry,你是說你們正把重點從前 50 家中心移到前 100 家嗎?
- President, CEO
- President, CEO
That's correct.
沒錯。
- Analyst
- Analyst
And how long do you expect that to last before that expands out further?
那你們預期這會持續多久,之後才會再進一步擴大?
- President, CEO
- President, CEO
Oh, we will look at it through first half of '08 and then look at what we need to do from an expansion standpoint. I would also say, Thom, that during that time frame, we are also completing our commercialization agreements with both J & J Animas, which by the end of this year, they will have some 200 people in the field, as well as additional work with Insulet and they will have somewhere close to 50 to 60 individuals in the field by the end of this year. So we really get the benefit of that, obviously, in that endeavor, although it's not an integrated product, we are certainly -- their teams are talking about the utilization of CGM along with their pump therapy, even as we speak.
噢,我們會先看到 08 年上半年,然後再評估從擴張角度我們需要做什麼。我也想說,Thom,在那段期間,我們也正在完成與 J & J Animas 的商業化協議;到今年年底,他們將有約 200 名外勤人員。此外,我們也會與 Insulet 進一步合作;到今年年底,他們外勤人員大約會接近 50 到 60 人。因此在這項推進上,我們確實能明顯受益。雖然這不是一個整合式產品,但我們當然——他們的團隊此刻也正在討論 CGM 與其幫浦治療併用的使用方式。
- Analyst
- Analyst
Got it. So they are not going to wait to market until middle of '09, they will get going later this year?
了解。所以他們不會等到 09 年年中才開始行銷,而是今年稍晚就會開始推動?
- President, CEO
- President, CEO
And quite frankly, our team members out in the field are already doing some informal co-marketing regardless of what management says.
坦白說,不管管理層怎麼說,我們在外勤的團隊成員其實已經在做一些非正式的共同推廣了。
- Analyst
- Analyst
What a surprise! And then help me out with manufacturing. You are going to have the -- you will have all manufacturing in your facility integrated in Q2 but then you've got a second vendor choice that you can do as volumes ramp up?
真令人意外!那再請你幫我釐清製造方面。你們會在第二季把所有製造整合到你們的廠內,但隨著量放大,你們還有第二家供應商選項可以用?
- President, CEO
- President, CEO
No. What that means is on the sensor side, we will relocate everything. We've got FDA approval to do all of the sensor manufacturing, all parts. The transmitter, the sensor and the receiver. Our goal has long been to use the experience of one of our largest vendors in order to do the receiver portion --
不是。我的意思是,在感測器端,我們會把所有項目都搬回來。我們已取得 FDA 核准,可以進行所有感測器製造、所有零組件。發射器、感測器與接收器。我們長期的目標是利用我們最大供應商之一的經驗來負責接收器部分——
- Analyst
- Analyst
Oh, okay.
喔,了解。
- President, CEO
- President, CEO
That dealt with the electronic equipment. We will outsource that.
那部分涉及電子設備。我們會外包。
- Analyst
- Analyst
Okay. And then last minor question, I suppose for Jess, is cash burn in the quarter was?
好的。最後一個小問題,我想是問 Jess:本季的現金消耗(cash burn)是多少?
- Interim CFO
- Interim CFO
We have been averaging about $10 to $11 million per quarter.
我們平均每季大約是 1,000 萬到 1,100 萬美元。
- Analyst
- Analyst
Okay.
好的。
- Interim CFO
- Interim CFO
We have fluctuated as low as $9 million.
最低曾波動到 900 萬美元。
- Analyst
- Analyst
Okay. So 35 to 40 for the year is what we should expect, '07?
好的。所以 07 年全年我們應該預期是 3,500 萬到 4,000 萬?
- Interim CFO
- Interim CFO
In '07, we were in the $40 million range, but we haven't given guidance on 2008.
在 07 年,我們大約在 4,000 萬美元的區間,但我們尚未對 2008 年提供指引。
- Analyst
- Analyst
Want to?
想給嗎?
- Interim CFO
- Interim CFO
No!
不想!
- Analyst
- Analyst
Okay.
好吧。
- President, CEO
- President, CEO
Nice try, Tom.
Tom,想得美。
- Analyst
- Analyst
All right, thanks, guys.
好,謝謝各位。
Operator
Operator
We will go next to Sara Michelmore with Cowen & Company.
接下來請 Cowen & Company 的 Sara Michelmore。
- Analyst
- Analyst
Can you talk a little bit at least in terms of the sequential plans here. You have two quarters under your belt where you have seen reasonably consistent quarter-to-quarter sequential growth. I know you don't want to talk about exact numbers but qualitatively, do you feel like we can comfortably model continued sequential quarterly increases for the revenue line?
你能不能至少從這裡的逐季規劃角度談一下?你們已經連續兩季看到相當一致的逐季成長。我知道你們不想談確切數字,但就質性而言,你覺得我們是否可以較有把握地在模型中假設營收線會持續逐季增加?
- President, CEO
- President, CEO
Yes.
是的。
- Analyst
- Analyst
Okay.
好的。
- President, CEO
- President, CEO
If we can't, I shouldn't be here.
如果不行,我就不該坐在這裡。
- Analyst
- Analyst
Okay. In terms of assembly, you are almost through this upgrade cycle here. Has that at all been time consuming in terms of the sales focus here? Should we think of you guys as having a little bit more sales resources coming out of that or was that something that you handled without distracting other sales/commercials part of business.
好的。就組裝而言,你們這次升級週期已經快完成了。這在銷售端的專注上是否有耗費時間?我們是否應該認為你們在完成後會有更多銷售資源釋出,還是說你們在處理這件事時並沒有分散業務中其他銷售/商業部分的注意力?
- President, CEO
- President, CEO
No, I think it was something that we handled without any issue with regards to the sales force. I think it was, you know always when you have a program like that, Sara, you are going to get a little pushback from some of the patients who will want to wait, in order to have the products in their hands rather than going ahead and knowing there will be a download available. I think our sales folks did an excellent job convincing patients that it would be better to have the product now and it would be simply be an Internet download at a later point. I think we did a good job in that category.
不,我認為我們在處理這件事時,對銷售團隊並沒有造成任何問題。我想你知道,Sara,當你有這樣的計畫時,總是會遇到一些病患的反彈,他們會想等到產品直接到手,而不是先行使用並知道之後會有下載可用。我認為我們的銷售人員做得非常好,說服病患現在就先拿到產品會更好,而之後只需要透過網路下載即可。我覺得我們在這方面做得不錯。
- Analyst
- Analyst
Okay. In terms of the R&D trajectory here, should we think about you spending about the same in absolute dollars that you did last year, or should we assume that that number is going to be up?
好的。就研發(R&D)支出走勢而言,我們應該把你們的絕對金額視為與去年差不多,還是應該假設那個數字會上升?
- President, CEO
- President, CEO
I -- I can't give you any guidance on that from the standpoint -- we are comfortable with what we have been spending on R&D.
我——我無法就此提供任何指引,從這個角度來說——我們對目前在研發上的支出水準感到滿意。
- Analyst
- Analyst
Okay. And the big projects are obviously in terms of dollar amounts are the hospital glucose monitoring and then the surgeon. Is that the way to think about the incremental dollar costs for you, the large --
好的。而大項目顯然在金額上主要是醫院血糖監測,然後是外科醫師(surgeon)。這樣理解你們增量美元成本的主要大項——
- President, CEO
- President, CEO
I would say that as -- yes. To the one side it certainly the IBBG program, but I would also say on the ambulatory sensor, we are already in humans with our fourth generation sensor, and we are in animals with our fifth generation sensor. Okay.
我會說是的——沒錯。一方面當然是 IBBG 計畫,但我也會說,就可攜式感測器而言,我們的第四代感測器已經在人體中使用,而第五代感測器則已在動物中使用。好的。
- Analyst
- Analyst
So I believe in strong iterations of developmental cycles, and so we are going to continue to pursue that strategy. Okay. Wonderful. And I think that's it for me for now. I will get back in the queue. Thanks.
所以我相信研發週期需要強力的反覆迭代,因此我們會持續推進這個策略。好的。太棒了。我想我目前就到這裡。我會回到隊列裡。謝謝。
- President, CEO
- President, CEO
Thanks, Sara.
謝謝你,Sara。
Operator
Operator
We will go next to Ben Andrew with William Blair.
接下來是 William Blair 的 Ben Andrew。
- Analyst
- Analyst
Good afternoon, Terry.
下午好,Terry。
- President, CEO
- President, CEO
Hi, Ben.
嗨,Ben。
- Analyst
- Analyst
A couple of quick things. Gross margin impact of the manufacturing and the facilities move, anything we should be looking for there or on the SG&A side?
幾個快速問題。製造與設施搬遷對毛利率的影響,有沒有什麼我們應該留意的,或是在 SG&A 端呢?
- Interim CFO
- Interim CFO
We did disclose that we had some additional fixed overhead costs. Right now, we do have two facilities, so that has increased the cost for the product.
我們確實揭露過有一些額外的固定間接費用。目前我們有兩個設施,因此產品成本有所增加。
- Analyst
- Analyst
Okay. And will that then normalize after what point?
好的。那這會在什麼時點之後恢復正常?
- Interim CFO
- Interim CFO
That would normalize as we gain -- as we scale the economy of our production. We intend to look at options on our prior headquarters facilities and potentially sublet that out.
當我們——隨著產量擴大、取得生產規模經濟時,就會恢復正常。我們打算評估先前總部設施的選項,並可能將其轉租出去。
- Analyst
- Analyst
Okay. So you haven't done that yet, though?
好的。所以你們目前還沒做這件事?
- Interim CFO
- Interim CFO
We have not done that as of today.
截至今天我們還沒有做。
- Analyst
- Analyst
Okay. And then if we think about the U.S. -- excuse me, the international market, Terry, you talked about the CE process there. How do you think about distribution and kind of scale of that opportunity in, say, '09, 2010?
好的。接著談到美國——不好意思,是國際市場,Terry,你提到那邊的 CE 流程。你怎麼看待在例如 2009、2010 年的通路與機會規模?
- President, CEO
- President, CEO
Yes, well, certainly in '09, we will launch the product in that domain. We've got certain centers that, we won't be in all 27 countries of the EU. We are going through the reimbursement strategy now, understanding what that's going to require. We do have target accounts already set up, given my previous experience, I'm currently in the process of interviewing a key individual that I have been previously associated with to handle our international experience, and distribution. So I would look to -- we've got a couple of different ways to go, as you know, the current relationship with our partners is U.S. only. We can learn to expand that, given their distribution thrust, particularly, obviously, J & J and/or alternatively look at a more traditional distribution with distributors that are certainly well known to me.
是的,嗯,當然在 2009 年我們會在那個區域推出產品。我們會先從特定中心開始,不會一開始就覆蓋歐盟 27 個國家。我們目前正在進行給付(reimbursement)策略,了解需要哪些要求。我們也已經建立了目標客戶名單;基於我過去的經驗,我目前正在面試一位我以前合作過的關鍵人選,來負責我們的國際業務與通路。因此我會認為——我們有幾種不同的路徑可走;如你所知,我們目前與合作夥伴的關係僅限美國。我們可以在他們的通路推進下學習並擴展,特別是很明顯的 J&J;或者,改採更傳統的模式,與我非常熟悉、知名的經銷商合作。
- Analyst
- Analyst
Sure, sure. Okay. Just a couple of other quick topics. You mentioned the JDRF trial is fully enrolled, and hopefully they'll see a data set out on an interim basis over the summer. Can they make ADA in your view, or is this more of a WADE likely target?
了解,了解。好的。再幾個快速主題。你提到 JDRF 試驗已完全收案,並希望在夏季能看到一份期中資料集。以你的看法,他們能趕上 ADA 嗎?還是更可能以 WADE 為目標?
- President, CEO
- President, CEO
That's a good question. I was just with Aaron Kowalski, who is the Director of Research. Their goal is possibly to talk about it at ADA, but until the data is in, and they have had a chance to analyze it, my guess is probably a little bit later.
這是個好問題。我剛和研究總監 Aaron Kowalski 在一起。他們的目標可能是在 ADA 上談這件事,但在資料出來、並且有機會分析之前,我猜可能會再晚一點。
- Analyst
- Analyst
Okay. Yes.
好的。是。
- President, CEO
- President, CEO
They are shooting for ADA.
他們確實以 ADA 為目標。
- Analyst
- Analyst
It sounds like it will be tight. And then under reimbursement process, I mean, we have had obviously, the movement on hics fix, you have the lot of the anecdotal evidence. You've got the JDRF trial pending. What do you think the blow-by-blow will be assuming the JDRF data are positive as we go into the back half of '08 and '09, and when we can get a national policy and, in fact, is that what you are looking for?
聽起來時間會很緊。然後在給付流程方面,我是說,我們顯然看到 hics fix 的進展,你也有很多軼事證據,還有 JDRF 試驗即將出結果。假設 JDRF 數據是正面的,你認為在 2008 年下半年到 2009 年的逐步進展會是什麼樣子?以及我們何時能拿到全國性政策?事實上,那是你們所期待的嗎?
- President, CEO
- President, CEO
That is what we are looking for, clearly. We currently have signed contracts. I can't disclose to you, because of the relationship of the contracts who they are, the payors, they are regional payors. I think we are continuing to expand that. But I would expect, as I have stated previously, that we have the opportunity for a national payer to possibly issue a coverage decision later this year. In '08. And then, of course it becomes a domino effect.
那確實是我們所期待的,毫無疑問。我們目前已簽署合約;我不能向你揭露付款方(payors)是誰,因為合約關係的緣故——它們是區域型付款方。我認為我們會持續擴大這些合作。但我預期,正如我先前所說,我們有機會讓某個全國性付款方可能在今年稍晚做出給付涵蓋決定——在 2008 年。之後當然就會產生骨牌效應。
- Analyst
- Analyst
Right. Right. Okay. Great. That's encouraging. And then the hospital product, anything you can tell us about what you are seeing with the performance of the product and kind of what the form factor, other details as you flush it out here through the animal testing that you can disclose?
對,對。好的。很好。這很令人鼓舞。然後關於醫院產品,你能否談談你們看到的產品表現,以及在動物測試推進過程中,你能透露的外形規格(form factor)或其他細節?
- President, CEO
- President, CEO
Yes, I mean, it -- when we did our last model -- I mean, we were absolutely 100% in the A region of the Clark Air Grid.
是的,我是說——在我們上一個模型中——我們在 Clark Air Grid 的 A 區域達到百分之百。
- Analyst
- Analyst
100%?
100%?
- President, CEO
- President, CEO
100%. We were totally within the requirements for therapeutic use, as is established by the Food and Drug Administration, and what that means, quite literally, is rather than trend and tracking that we have with the ambulatory sensor, this is therapeutic use that physicians and healthcare providers could make insulin adjustment decisions based on that data. That said, it's in a -- it's a small number. We will be back into humans later this month. Again, on a prospective basis. So we couldn't be more thrilled with the outcome of what we are seeing in these clinical trials and really significant progress made in this particular sector.
100%。我們完全符合美國食品藥物管理局所建立、用於治療用途的要求。這在字面上的意思是:不同於我們可攜式感測器所做的趨勢與追蹤,這是治療用途,醫師與醫療照護提供者可以根據這些數據做胰島素調整決策。話雖如此,樣本數仍然不大。我們會在本月稍晚回到人體試驗,同樣以前瞻性方式進行。因此我們對於在這些臨床試驗中看到的結果感到非常振奮,而且在這個領域取得了非常顯著的進展。
- Analyst
- Analyst
Have you seen 100% region A before, Terry, in your experience?
Terry,以你的經驗,你以前看過 100% 都在 A 區域嗎?
- President, CEO
- President, CEO
No.
沒有。
- Analyst
- Analyst
I have not, so that's surprising. And then anything you can say about Gen 4 and 5 in terms of changes on the ambulatory product or other performance parameters, is it implementing some of the things from the hospital, is there any crossover there? What are the directional changes you are looking at?
我也沒有,所以這很令人驚訝。那麼關於第 4 代與第 5 代,在可攜式產品的變更或其他效能參數方面,你能說些什麼嗎?是否導入了醫院產品的一些做法?兩者之間有沒有交叉?你們想要的方向性變化是什麼?
- President, CEO
- President, CEO
Yes. We look at it in two different -- they cross over to each other from a standpoint, things that we learn about in the ambulatory sensor, with respect to membrane technology, which we really are exquisite with, in order to reduce noise, that's been one of the reasons we are able to go out seven, now ten days if you look at the trial that's going to be presented at ADA. We understand the membranes quite well. We have been able to leverage that over to the hospital side, because there's obviously a large number of drugs administered in the ICU. We are able to demonstrate lack of significant drug interference. On the same side, looking at development work from our ibbg, in order to get those kind of Clark Air Grid and MARD, there's some configuration that we will go back to the ambulatory side. Right now they are both driving each other from the third generation is more membrane related, and the -- I'm sorry, fourth generation and the fifth generation is both membrane and electrochemistry related.
有的。我們從兩個不同——它們彼此之間會交叉:就可攜式感測器而言,我們在膜(membrane)技術方面學到的東西——我們在這方面非常精細——用來降低雜訊;這也是我們能做到 7 天、現在甚至 10 天(如果你看將在 ADA 發表的試驗)的原因之一。我們對膜的理解相當深入。我們也把這些能力延伸到醫院端,因為在加護病房(ICU)會使用大量藥物。我們能證明沒有顯著的藥物干擾。另一方面,從我們的 IBBG 研發工作來看,為了達到那樣的 Clark Air Grid 與 MARD,有一些配置我們會再帶回可攜式端。目前兩邊彼此驅動:第三代比較偏膜相關,而——抱歉——第四代與第五代則同時與膜與電化學相關。
- Analyst
- Analyst
Great. Very helpful. Thanks, Terry.
很好。非常有幫助。謝謝你,Terry。
Operator
Operator
We will hear next from Bill Plovanic with Canaccord Adams.
接下來我們聽 Canaccord Adams 的 Bill Plovanic。
- Analyst
- Analyst
Good evening.
晚安。
- President, CEO
- President, CEO
Hi, Bill.
嗨,Bill。
- Analyst
- Analyst
Lots has been asked. Two follow-ups. Just in terms of blocking and tackling on the reimbursement front, I know you can't give names. Are you willing to give, like, number of lives covered at this point in terms of contracts signed just to give us a yardstick to measure by?
已經問了很多。我有兩個追問。就給付端的基本功與執行面來說,我知道你不能提供名稱。你是否願意提供例如目前已簽約所涵蓋的人口數(number of lives covered),讓我們有個衡量的標尺?
- President, CEO
- President, CEO
Well, I'm reluctant to do that, obviously, from some competitive reasons. I will just say that we have made great progress. We have -- although still regionally based and we need to understand that, but it is moving in a very positive direction.
嗯,基於一些競爭方面的原因,我不太願意這麼做。我只能說我們已取得很大進展。我們——雖然仍以區域為主、而且我們需要理解這一點——但整體正朝非常正面的方向前進。
- Analyst
- Analyst
Okay. And then I think in the past you have given us a feel for the number of sensors placed or sold in the period. I just wonder if you would be willing to share that data with us again.
好的。接著我想,過去您曾讓我們大致了解在該期間內放置或售出的感測器數量。我想請問您是否願意再次與我們分享那項數據。
- President, CEO
- President, CEO
I'm not sure I have done that in the past. I'm getting a lot of shaking of the heads around the table, so I'm -- no. No. They are telling me no. So --
我不確定我過去是否有做過這件事。我看到桌邊很多人都在搖頭,所以我——不。不是。他們跟我說不行。所以——
- Analyst
- Analyst
Okay. Then in terms of the upgrade, I believe when we -- we last talked, it was, I think $150 roughly per system. Is that going to continue in the future?
好的。那麼就升級而言,我記得我們——我們上次談到時,每套系統大約是 150 美元左右。未來也會持續如此嗎?
- President, CEO
- President, CEO
Well, we are trying to get all of these upgrades done in the next 30 days, basically. So at this point, we are winding that down. My -- my goal here is to be out of STS three-day production by the end of this month.
嗯,我們基本上正努力在接下來 30 天內把這些升級全部完成。所以就目前而言,我們正在逐步收尾。我——我的目標是在本月底前退出 STS 三日產品的生產。
- Analyst
- Analyst
I guess the question on top of that is, a little over 1200 of the 4300 on the three-days have been replaced. It doesn't seem like the other 3,000 or so you sound very optimistic that those are going to switch over or is that kind of the push in the month of January -- or in the first quarter, we will see more of those in kind of a bigger number as we -- as we end out?
我想在此之上的問題是,三日產品 4,300 套中,略多於 1,200 套已經被替換。看起來其餘大約 3,000 套,您聽起來非常樂觀它們會轉換過來;還是說這會是 1 月份的推動——或是在第一季,我們會看到更多、數量更大的轉換,隨著我們——隨著我們收尾?
- SVP, Corporate Affairs
- SVP, Corporate Affairs
Yes, Bill, this is Steve. You hit it right. The number that we released today was as of 12/31. We will obviously give another update. We continued to make a big push here in the first quarter and we will wind that down by the end of this month, but we will give another update, kind of an aggregate. As we've indicated previously that we'd like to get some more metrics on the business and we would be able to do that in first quarter call.
是的,Bill,我是 Steve。你說得沒錯。我們今天公布的數字是截至 12/31 的。我們當然會再提供一次更新。我們在第一季持續大力推動,並會在本月底前把這件事收尾,但我們會再提供一次更新,算是一個彙總。正如我們先前所表示的,我們希望取得更多關於業務的指標,而我們將能在第一季電話會議上提供。
- Analyst
- Analyst
Okay. That's all I had. Thanks so much.
好的。我就這些。非常感謝。
Operator
Operator
Our final question will come from Mimi Pham with JMP Securities.
我們最後一個問題來自 JMP Securities 的 Mimi Pham。
- Analyst
- Analyst
Hi, good afternoon. Going off of Sara's question on sales growth in 2008. Do you think you can keep this sequential sensor growth rate in the high 30s and the new patient adds at the 700 to 900 range per quarter through '08?
嗨,午安。延續 Sara 關於 2008 年銷售成長的問題。您認為在 2008 年,感測器的季增成長率能維持在 30% 高段,且每季新增病患數能維持在 700 到 900 的區間嗎?
- President, CEO
- President, CEO
We don't give those projections, Mimi. I can only tell you that as reimbursement broadens, that we obviously feel that that's the number one barrier to adoption. So it will be contingent to some degree, we are seeing good positive movement in that but I would hate to predict not knowing exactly what the reimbursement landscape is going to look like as we go forward this year.
Mimi,我們不提供那些預測。我只能告訴你,隨著給付範圍擴大,我們顯然認為那是採用的第一大障礙。因此在某種程度上會取決於此;我們確實看到良好且正向的進展,但在我不確定今年接下來給付環境會長什麼樣的情況下,我不想做預測。
- Analyst
- Analyst
Well, can you comment, does that sound conservative or is that probably like a --
那您能評論一下嗎?那聽起來是保守的,還是可能像是——
- President, CEO
- President, CEO
Mimi, I can't really comment. You have to make your models based on available information, and don't put me in a situation where, I see it in print and I have to live up to that expectation.
Mimi,我真的無法評論。你必須根據可得資訊建立你的模型,也別讓我陷入那種情況:我在印刷品上看到它,然後我就得達到那個期待。
- Analyst
- Analyst
Okay. On the critical care product, can you give us a ballpark per pricing -- per day pricing. I'm assuming something premium to the $8 per day for the Seven.
好的。關於重症照護產品,您能給我們一個大概的定價——每日定價的區間嗎?我猜應該會比 Seven 每天 8 美元更高。
- President, CEO
- President, CEO
Yes. It would be premium to $8 a day for the Seven. We haven't even talked about pricing with our potential partners at this point. So it would be -- I think it's in feasibility stage, and we haven't vetted that through exactly what our costs would be and therefore, what our end pricing would be.
是的。它會高於 Seven 每天 8 美元。我們目前甚至還沒有和潛在合作夥伴談過定價。所以它會——我認為目前仍在可行性階段,我們也尚未釐清我們的成本,因此也還無法確定最終定價。
- Analyst
- Analyst
Okay. And then is there a way to give us a sort of ballpark number of patients you think you are reaching, potential patients you think you are reaching at these 50 centers that you concentrated on. I'm trying to get a sense of 6,000 patients you've had so far that purchased the STS, what that penetration is.
好的。那麼,有沒有辦法給我們一個大概的數字:在你們聚焦的這 50 個中心,你們認為能觸及多少病患、多少潛在病患?我想了解一下,到目前為止購買 STS 的 6,000 名病患,這樣的滲透率大概是多少。
- President, CEO
- President, CEO
Well, you know, we kind of set the standard that they had to have at least somewhere north of 1500 patients, type I patients at a particular center to call it one of our key target centers and obviously that ranges from that number to well beyond that, if you look at some of the centers that we call on, Jocelyn as an example or some of the other larger centers. So I don't think we have a total population of patients within those centers that we currently have identified.
嗯,你知道,我們大致訂了一個標準:某個中心至少要有 1,500 名以上的第一型糖尿病病患,我們才會把它稱為我們的關鍵目標中心之一;而且顯然這個數字從那個水準到遠高於此都有,若你看我們拜訪的一些中心,例如 Jocelyn,或其他更大型的中心。所以我不認為我們目前有一個在這些中心內、我們已辨識出的病患總人口數。
- Analyst
- Analyst
Would you characterize the next 50 centers that you are going after to be similar in terms of patient size?
那您會把接下來要攻的 50 個中心,描述為在病患規模上也類似嗎?
- President, CEO
- President, CEO
Yes, they would typically now be in -- what I will call less -- areas where they are not as concentrated. The goal here has been spend as much time to train the physicians. Obviously, we think that we have done an excellent job of that, not only domestically but quite frankly when we were at the Prague meeting, we were the darling of the meeting but also I think even more important than that was the concept that glycemic variability is becoming such a common term and so from that standpoint, that message is now resonating from the key opinion leaders. We need to get that out to really the rank and the file who treat the bulk of the disease. And so they are at less than those -- well, I will call it the real urban centers. We don't want our sales folks spending a lot of windshield time driving from one location to another. So we will expand it when it makes sense.
是的,它們通常會位於——我會稱之為較不——集中的地區。這裡的目標是花盡可能多的時間訓練醫師。顯然,我們認為我們在這方面做得非常出色,不僅在國內;坦白說,在布拉格會議上,我們是會議的寵兒。但我認為更重要的是,「血糖變異性」這個概念正變得非常普遍;因此從這個角度來看,這個訊息現在正由關鍵意見領袖產生共鳴。我們需要把它傳遞給真正治療大多數病患的基層醫護人員。因此他們所在的位置不如那些——嗯,我會稱之為真正的都會中心。我們不希望我們的銷售人員花很多時間在路上開車從一個地點到另一個地點。所以我們會在合理的時候擴張。
- Analyst
- Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
And, gentlemen, I will turn the conference back to you for closing remarks.
那麼,各位先生,我把電話會議交回給你們做結語。
- President, CEO
- President, CEO
Well, again, great year. We're running hard in the first quarter. I'm very pleased with the performance of the company, and I look forward to updating you at the close of the first quarter of 2008. We're making a huge impact in the way patients are being treated. We're making a huge impact in the way physicians are better able to help their patients avoid some of the negative aspects and clinical applications of excessive glycemic variability and I look forward to keeping you informed. Thank you.
嗯,再次強調,這是很棒的一年。我們在第一季會全力衝刺。我對公司的表現非常滿意,也期待在 2008 年第一季結束時向各位更新。我們正在對病患接受治療的方式產生巨大影響。我們也正在對醫師更能協助病患避免過度血糖變異性的一些負面影響與臨床應用,產生巨大影響。我也期待持續讓各位掌握最新進展。謝謝。
Operator
Operator
That concludes today's conference call. Have a pleasant day.
今天的電話會議到此結束。祝各位有個愉快的一天。